RARECast

Podcast autorstwa RARECast - Czwartki

Czwartki

Kategorie:

532 Odcinki

  1. How One Patient Organization Leverages Research Investments

    Opublikowany: 23.05.2024
  2. Charging into the Storm

    Opublikowany: 16.05.2024
  3. A Gene Therapy Developer that Embraces Different Models for Reaching Patients

    Opublikowany: 9.05.2024
  4. Using Directed Evolution to Develop New Vectors for Genetic Medicines

    Opublikowany: 2.05.2024
  5. Addressing a Shortage of Genetic Counselors with AI

    Opublikowany: 25.04.2024
  6. A Small Molecule Therapy to Regenerate Muscle in People with DMD

    Opublikowany: 18.04.2024
  7. Forging a Faster Path for Gene Therapies

    Opublikowany: 11.04.2024
  8. Determining the Value of Rare Disease Therapies

    Opublikowany: 4.04.2024
  9. Buying and Building a Gene Therapy Presence

    Opublikowany: 28.03.2024
  10. A Clinical Trial Failure Derails a Promising Technology

    Opublikowany: 21.03.2024
  11. Helping People with Undiagnosed Rare Diseases Find Answers

    Opublikowany: 14.03.2024
  12. Speeding and Scaling the Development of Genome Editing Therapies

    Opublikowany: 7.03.2024
  13. Getting a Next-Generation Genome Editing Therapy for Sickle Cell Disease Back on Track

    Opublikowany: 29.02.2024
  14. Trying to Break a Leg in a Wheelchair

    Opublikowany: 22.02.2024
  15. A Drug Developer that Makes Pediatric Cancers a Priority

    Opublikowany: 15.02.2024
  16. Harnessing the Body’s Natural RNA Machinery to Treat Diseases

    Opublikowany: 8.02.2024
  17. Targeting the Leading Cause of Death in Friedreich’s Ataxia with a Gene Therapy

    Opublikowany: 1.02.2024
  18. How Inhaled mRNA May Help Rare Disease Patients Breathe Easier

    Opublikowany: 25.01.2024
  19. Changing What’s Possible with Cell and Gene Therapies

    Opublikowany: 18.01.2024
  20. Why Flying with a Wheelchair Is a Civil Rights Issue

    Opublikowany: 11.01.2024

3 / 27

RARECast is a Global Genes podcast hosted by award-winning journalist Daniel Levine. It focuses on the intersection of rare disease with business, science, and policy.

Visit the podcast's native language site